

# Review of: "[Commentary] The Polyfollicular Anovulatory Androgenic Syndrome: A New Label for an Old Syndrome"

Stanley Andrisse<sup>1</sup>

<sup>1</sup> Howard University

**Potential competing interests:** No potential competing interests to declare.

I agree with this statement from the abstract, "there is an obvious need for a new name to reflect these abnormalities." Regarding this statement, "the primary signal for the syndrome seems to be insulin resistance and hyperinsulinemia", this is still highly debated in the field. Regarding this statement, "increased ovarian androgen production with subsequent hyperandrogenemia.", depending on the diagnostic criteria, some people with diagnosed PCOS don't display hyperandrogenemia. I am not in favor nor opposed to the proposed naming, "Polyfollicular Anovulatory Androgenic Syndrome" (PAAS). I feel that this is conversation that needs to be addressed at the "scientific society" level, such as the Androgen Excess and PCOS (AEPCOS, <https://ae-society.org/>), etc. This may bring into conversation the name change of AEPCOS. In the new description of the 3 phenotypes, the author continues to use the word "polycystic" despite just telling the reader the inaccuracy of this wording. I suggest changing this.